Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Terrault discusses results from key viral hepatitis studies reported at the American Association for the Study of Liver Diseases (AASLD) 2020 annual conference, The Liver Meeting Digital Experience, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.
Norah Terrault, MD, MPH
Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California
Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)
Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment
Clinical Care Options (CCO) expert audio: Dr Pietro Lampertico discusses the importance of continued HBV monitoring in patients without indications for immediate treatment
Dr Norah Terrault: missed opportunities for hepatitis delta virus (HDV) testing and how to overcome them, from Clinical Care Options (CCO)